Impact Biomedical Inc. (NYSEAMERICAN:IBO – Free Report)’s stock is going to reverse split on Wednesday, September 23rd. The 1-12.62 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, September 22nd.
Impact Biomedical Price Performance
Shares of NYSEAMERICAN IBO opened at $0.48 on Tuesday. The business has a fifty day moving average of $0.46 and a two-hundred day moving average of $0.52. Impact Biomedical has a 52-week low of $0.37 and a 52-week high of $0.83.
Impact Biomedical Company Profile
Impact Biomedical, Inc (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc, which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.
See Also
- Five stocks we like better than Impact Biomedical
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Impact Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impact Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
